Covenant Asset Management, LLC Neurocrine Biosciences Inc Transaction History

Covenant Asset Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 02, 2024	BUY	$130.86 - $143.19 $4,841 - $5,298	37 Added 0.13%	28,343 $3.9 Million
Q1 2024 Apr 23, 2024	BUY	$130.4 - $143.74 $69,764 - $76,900	535 Added 1.93%	28,306 $3.9 Million
Q4 2023 Jan 22, 2024	SELL	$106.07 - $132.76 $241,839 - $302,692	-2,280 Reduced 7.59%	27,771 $3.66 Million
Q3 2023 Oct 31, 2023	BUY	$94.02 - $117.1 $1.09 Million - $1.36 Million	11,628 Added 63.12%	30,051 $3.38 Million
Q2 2023 Jul 12, 2023	SELL	$89.53 - $104.87 $7,610 - $8,913	-85 Reduced 0.46%	18,423 $1.74 Million
Q1 2023 Apr 27, 2023	BUY	$94.11 - $123.02 $1.74 Million - $2.28 Million	18,508 New	18,508 $1.87 Million

627

94.3M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12.2B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Covenant Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Covenant Asset Management, LLC with notifications on news.